MET: A promising anticancer therapeutic target

Solange Peters, Alex A. Adjei

Research output: Contribution to journalReview articlepeer-review

226 Scopus citations


The MET pathway is dysregulated in many human cancers and promotes tumour growth, invasion and dissemination. Abnormalities in MET signalling have been reported to correlate with poor clinical outcomes and drug resistance in patients with cancer. Thus, MET has emerged as an attractive target for cancer therapy. Several MET inhibitors have been introduced into the clinic, and are currently in all phases of clinical trials. In general, initial results from these studies indicate only a modest benefit in unselected populations. In this Review, we discuss current challenges in developing MET inhibitors-including identification of predictive biomarkers-as well as the most-efficient ways to combine these drugs with other targeted agents or with classic chemotherapy or radiotherapy.

Original languageEnglish (US)
Pages (from-to)314-326
Number of pages13
JournalNature Reviews Clinical Oncology
Issue number6
StatePublished - Jun 2012

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'MET: A promising anticancer therapeutic target'. Together they form a unique fingerprint.

Cite this